Your session is about to expire
← Back to Search
Chemotherapy
Proton Therapy for Anal Cancer
Phase 2
Waitlist Available
Led By Jordan Kharofa, MD
Research Sponsored by Jordan Kharofa
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial Must have
Be older than 18 years old
Timeline
Screening 3 weeks
Treatment Varies
Follow Up every 6 months up to 60 months
Awards & highlights
Approved for 5 Other Conditions
No Placebo-Only Group
All Individual Drugs Already Approved
Summary
This trial is testing if Proton Therapy can reduce radiation exposure to healthy areas around anal cancer, aiming to lessen side effects compared to standard treatments. Proton therapy is an emerging treatment for cancer that may have distinct advantages over conventional radiotherapy, particularly in minimizing radiation dose to surrounding normal tissue.
Who is the study for?
This trial is for individuals with a specific type of anal cancer (squamous or basaloid carcinoma) that's at a certain stage (T2-4, any N category). Participants must be relatively active and able to care for themselves (Karnofsky Performance Status >70%). Those expected to live less than 3 months cannot join.
What is being tested?
The study is testing if Proton Therapy can reduce the radiation received by healthy tissues around anal cancer compared to standard therapy. The goal is to see if this method lowers side effects while treating the cancer effectively.
What are the potential side effects?
Potential side effects may include skin reactions, fatigue, digestive issues like nausea or diarrhea from chemotherapy, and other typical reactions associated with radiation therapy.
Timeline
Screening ~ 3 weeks3 visits
Treatment ~ Varies
Follow Up ~ every 6 months up to 60 months
Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~every 6 months up to 60 months
Treatment Details
Study Objectives
Study objectives can provide a clearer picture of what you can expect from a treatment.Primary study objectives
Rates of Acute Toxicity
Secondary study objectives
Complete Response Rate
Distant Metastases Free Survival
Local Progression Free Survival
+3 moreAwards & Highlights
Approved for 5 Other Conditions
This treatment demonstrated efficacy for 5 other conditions.
No Placebo-Only Group
All patients enrolled in this study will receive some form of active treatment.
All Individual Drugs Already Approved
Therapies where all constituent drugs have already been approved are likely to have better-understood side effect profiles.
Trial Design
1Treatment groups
Experimental Treatment
Group I: Proton Therapy and ChemotherapyExperimental Treatment2 Interventions
Standard chemoradiation using 5-FU, Mitomycin, with pencil beam proton radiotherapy
Treatment
First Studied
Drug Approval Stage
How many patients have taken this drug
Mitomycin
FDA approved
Proton therapy
2011
N/A
~30
Research Highlights
Information in this section is not a recommendation. We encourage patients to speak with their healthcare team when evaluating any treatment decision.Mechanism Of Action
Side Effect Profile
Prior Approvals
Other Research
Radiation therapy, including proton therapy, is a common treatment for anal cancer. It works by using high-energy particles or waves, such as X-rays or protons, to damage the DNA of cancer cells, which inhibits their ability to grow and divide.
Proton therapy is a type of targeted radiation delivery that allows for more precise targeting of the tumor while minimizing damage to surrounding healthy tissues. This precision is particularly important for anal cancer patients because it reduces the risk of side effects and complications, thereby improving the patient's quality of life during and after treatment.
Find a Location
Who is running the clinical trial?
Jordan KharofaLead Sponsor
1 Previous Clinical Trials
Jordan Kharofa, MDPrincipal InvestigatorUniversity of Cincinnati
1 Previous Clinical Trials
Media Library
Eligibility Criteria:
This trial includes the following eligibility criteria:- Your cancer has spread beyond its original location (Stage T2-4) and may have spread to nearby lymph nodes (any N category).Doctors do not expect you to live more than 3 months.
Research Study Groups:
This trial has the following groups:- Group 1: Proton Therapy and Chemotherapy
Awards:
This trial has 3 awards, including:- Approved for 5 Other Conditions - This treatment demonstrated efficacy for 5 other conditions.
- No Placebo-Only Group - All patients enrolled in this study will receive some form of active treatment.
- All Individual Drugs Already Approved - Therapies where all constituent drugs have already been approved are likely to have better-understood side effect profiles.
Timeline:
This trial has the following timeline:- Screening: It may take up to 3 Weeks to process to see if you qualify in this trial.
- Treatment: The duration you will receive the treatment varies.
- Follow Ups: You may be asked to continue sharing information regarding the trial for 6 Months after you stop receiving the treatment.